ABUS / Arbutus Biopharma clinical hold slows hepatitis B momentum: broker

WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage more_horizontal

Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA more_horizontal

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will b more_horizontal

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to lo more_horizontal

WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging more_horizontal

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st more_horizontal

Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year. more_horizontal

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to lo more_horizontal